Blood-Brain Barrier
Restricts Entry
A DIFFERENT APPROACH
Put the therapeutic where the biology is.
Aila is designed to cross the blood–brain barrier, generate a therapeutic biologic within the CNS and regulate expression with a small-molecule switch.
01 Access
02 Local expression
03 Control
04 Safe
OUR TECHNOLOGY
PROPRIETARY DELIVERY ARCHITECTURE
Targeted
Specific +
Controlled
Therapeutic Payload
Specific + Controlled
Brain
Access
AI guided biologic
development
CNS access
IV delivery
Promoter + Small-molecule control
Treg-targeted signalling
Brain Penetrant AAV
Cell Specific + controlled
Safe
Healing CNS
small molecule
LEAD PROGRAMME · AILA-001
Inflamed CNS
Restoring immune balance within the brain.
AILA-001 is being developed for Primary Progressive Multiple Sclerosis. It is designed to produce a Treg-biased biologic locally in the CNS, expand regulatory T cells and counter compartmentalised neuroinflammation.
Aila-001
+
small molecule
Healing CNS
Expand natural anti-inflammatory regulatory T cells
Disease-modifying activity
at a fraction of conventional vector dose
Ultra-low systemic exposure
Enhanced safety profile
Reduced liver burden
Minimized off-target toxicity
Improved manufacturability
Lower vector input requirements
Lower cost of goods
Reduced COGS potential
Commercial scalability
Enables broader patient access
